Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Nichi-Iko Pharmaceutical Co Ltd (4541)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Nichi Iko Pharmaceutical historical data, for real-time data please try another search
35.0 0.0    0.00%
28/03 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3687200000 
  • Volume: 0
  • Bid/Ask: 35.0 / 36.0
  • Day's Range: 35.0 - 36.0
Nichi Iko Pharmaceutical 35.0 0.0 0.00%

4541 Balance Sheet

 
Featured here, the Balance Sheet for Nichi-Iko Pharmaceutical Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2022
31/12
2022
30/09
2022
30/06
2022
31/03
Total Current Assets 169513 177124 156366 155391
Cash and Short Term Investments 12502 13344 10342 15730
Cash - - - -
Cash & Equivalents 12341 12989 9987 15305
Short Term Investments 161 355 355 425
Total Receivables, Net 75309 70338 51473 38605
Accounts Receivables - Trade, Net 75295 70338 51473 38605
Total Inventory 77867 87127 90238 95745
Prepaid Expenses - - - -
Other Current Assets, Total 3835 6315 4313 5311
Total Assets 234621 246558 266215 260559
Property/Plant/Equipment, Total - Net 35188 35894 40511 39289
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - 20321 18479
Intangibles, Net 19852 22167 41505 39609
Long Term Investments 10060 11364 7500 7779
Note Receivable - Long Term 14 - - -
Other Long Term Assets, Total 3 3 3 3
Other Assets, Total 6559 23465 43442 62885
Total Current Liabilities 191110 182556 157838 147471
Accounts Payable 42815 40650 43210 48123
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt 134082 129138 101771 60881
Current Port. of LT Debt/Capital Leases - - - 24647
Other Current liabilities, Total 14213 12768 12857 13820
Total Liabilities 286722 282184 253767 246786
Total Long Term Debt 69055 71808 74293 77102
Long Term Debt 69055 71808 74293 77102
Capital Lease Obligations - - - -
Deferred Income Tax 9557 10685 9713 10160
Minority Interest -147 56 227 379
Other Liabilities, Total -320071 -313005 -252705 -211837
Total Equity -52101 -35626 12448 13773
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 25975 25975 25975 25975
Additional Paid-In Capital 24511 24511 24511 24511
Retained Earnings (Accumulated Deficit) -127167 -110715 -59969 -55657
Treasury Stock - Common -2049 -2053 -2119 -2124
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 26629 26656 24050 21068
Total Liabilities & Shareholders' Equity 234621 246558 266215 260559
Total Common Shares Outstanding 70.47 70.47 70.44 70.43
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4541 Comments

Write your thoughts about Nichi-Iko Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email